Skip to content

RITUAL Ultivision AI CADe Randomized Controlled Trial

Randomized Clinical Trial of the Ultivision AI Artificial Intelligence System for Colorectal Cancer Screening or Surveillance in Colonoscopy

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05732233
Acronym
RITUAL
Enrollment
137
Registered
2023-02-16
Start date
2023-07-21
Completion date
2024-02-23
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma Colon, Colon Adenoma, Polyp of Colon

Keywords

Screening, Surveillance, Artificial Intelligence, Colonoscopy

Brief summary

Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas). Ultivision AI CADe is indicated for white light colonoscopy only.

Detailed description

Ultivision AI contains an image processing software and algorithm based on machine learning technology and convolutional neural networks (CNN). The algorithm's primary function is to identify and highlight the likelihood of the presence of a colon polyp.

Interventions

DEVICEUltivision AI

Ultivision AI is a computer-assisted detection (CADe) device intended to aid endoscopists in the real-time identification of colonic mucosal lesions (such as polyps and adenomas) in adult patients undergoing colorectal cancer screening and surveillance examinations.

Sponsors

Meditrial USA Inc.
CollaboratorINDUSTRY
Satisfai Health, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Masking description

Pathologist is blind to group assignment

Intervention model description

Parallel trial design

Eligibility

Sex/Gender
ALL
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Age 45 to 75 years; 2. Screening or surveillance colonoscopy. 3. Iinformed consent

Exclusion criteria

1. Colorectal cancer; 2. Inflammatory bowel disease, including Crohn's disease or ulcerative colitis; 3. Polyposis syndrome including Familial Adenomatous Polyposis, Cowden syndome, Linch syndrome, Peutz-Jeghers syndrome, MUITYH associated polyposis, familial Colorectal Cancer type X; 4. Positive Fecal Immunochemical Test; 5. Use anti-platelet agents or anticoagulants that prevent polyps removal; 6. Colon resection, not including the appendix; 7. Subject is pregnant or lactating.

Design outcomes

Primary

MeasureTime frameDescription
Adenoma per Colonoscopy (APC)During the procedure/surgerySuperiority of Ultivision-AI arm versus control arm. APC is defined as the total number of histologically confirmed adenomas resected divided by the total number of colonoscopies.
Adenoma Per Extraction (APE).During the procedure/surgeryNon inferiority of Ultivision-AI arm versus control arm. Where APE is the fraction of adenoma, sessile serrated lesions, and large (\>10mm) hyperplastic polyps of the proximal colon (caecum, ascending colon, hepatic flexure, and transverse colon) out of total number of resections.

Countries

Canada, Italy, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026